NCT02018627View on ClinicalTrials.gov

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 2, 2018

Study Completion Date

August 2, 2018

Conditions
Type 1 Diabetes
Interventions
DRUG

Xeris glucagon

The subject is given an injection of xeris glucagon

DRUG

Lilly glucagon

The subject is given an injection of lilly glucagon

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Steven J. Russell, MD, PhD

OTHER

NCT02018627 - Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon | Biotech Hunter | Biotech Hunter